MaxCyte, Inc. Gross Profit
MaxCyte, Inc. (MXCT) reported Gross Profit of $5.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:GrossProfit · last filed 2026-08-13
- MaxCyte, Inc. gross profit for the quarter ending 2026-06-30 was $5.60M, a 19.92% decline year-over-year.
- MaxCyte, Inc. gross profit for the quarter ending 2026-03-31 was $8.08M, a 9.12% decline year-over-year.
- MaxCyte, Inc. gross profit for the quarter ending 2025-12-31 was $5.69M, a 11.26% decline year-over-year.
- MaxCyte, Inc. gross profit for the quarter ending 2025-09-30 was $5.23M, a 16.08% decline year-over-year.
- MaxCyte, Inc. gross profit for fiscal 2025 was $26.80M, a 14.98% decline from fiscal 2024.
- MaxCyte, Inc. gross profit for fiscal 2024 was $31.53M, a 13.73% decline from fiscal 2023.
- MaxCyte, Inc. gross profit for fiscal 2023 was $36.55M, a 6.68% decline from fiscal 2022.
- MaxCyte, Inc. gross profit for fiscal 2022 was $39.16M, a 29.48% increase from fiscal 2021.
| Period end | Gross Profit 3 month | Gross Profit 3 month as first filed | Gross Profit 6 month | Gross Profit 6 month as first filed | Gross Profit 9 month | Gross Profit 9 month as first filed | Gross Profit 12 month | Gross Profit 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.60M 10-Q · filed 2026-08-13 | $13.68M 10-Q · filed 2026-08-13 | $19.37M derived: sum of 3 quarters · filed 2026-08-13 | $24.60M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $8.08M 10-Q · filed 2026-05-13 | $13.77M derived: sum of 2 quarters · filed 2026-05-13 | $19.00M derived: sum of 3 quarters · filed 2026-05-13 | $25.99M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $10.92M derived: sum of 2 quarters · filed 2026-03-25 | $17.91M derived: sum of 3 quarters · filed 2026-08-13 | $26.80M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $5.23M 10-Q · filed 2025-11-13 | $12.22M derived: sum of 2 quarters · filed 2026-08-13 | $21.11M 10-Q · filed 2025-11-13 | $27.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $6.99M 10-Q · filed 2026-08-13 | $15.88M 10-Q · filed 2026-08-13 | $22.29M derived: sum of 3 quarters · filed 2026-08-13 | $28.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $8.89M 10-Q · filed 2026-05-13 | $15.30M derived: sum of 2 quarters · filed 2026-05-13 | $21.54M derived: sum of 3 quarters · filed 2026-05-13 | $30.48M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $12.65M derived: sum of 2 quarters · filed 2026-03-25 | $21.59M derived: sum of 3 quarters · filed 2026-03-25 | $31.53M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $6.24M 10-Q · filed 2025-11-13 | $15.18M derived: sum of 2 quarters · filed 2025-11-13 | $25.11M 10-Q · filed 2025-11-13 | $39.21M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $8.94M 10-Q · filed 2025-08-06 | $18.88M 10-Q · filed 2025-08-06 | $32.97M derived: sum of 3 quarters · filed 2025-08-06 | $40.18M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $9.94M 10-Q · filed 2025-05-08 | $24.03M derived: sum of 2 quarters · filed 2025-05-08 | $31.24M derived: sum of 3 quarters · filed 2025-05-08 | $38.91M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $14.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $21.30M derived: sum of 2 quarters · filed 2025-03-11 | $28.97M derived: sum of 3 quarters · filed 2025-03-11 | $36.55M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $7.21M 10-Q · filed 2024-11-06 | $7.21M 10-Q · filed 2023-11-08 | $14.88M derived: sum of 2 quarters · filed 2024-11-06 | $22.45M 10-Q · filed 2024-11-06 | $22.45M 10-Q · filed 2023-11-08 | $33.33M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $7.67M 10-Q · filed 2024-08-06 | $7.67M 10-Q · filed 2023-08-09 | $15.24M 10-Q · filed 2024-08-06 | $15.24M 10-Q · filed 2023-08-09 | $26.12M derived: sum of 3 quarters · filed 2024-08-06 | $35.39M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $7.58M 10-Q · filed 2024-05-07 | $7.58M 10-Q · filed 2023-05-10 | $18.45M derived: sum of 2 quarters · filed 2024-05-07 | $27.73M derived: sum of 3 quarters · filed 2024-05-07 | $36.21M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $20.15M derived: sum of 2 quarters · filed 2024-03-12 | $28.64M derived: sum of 3 quarters · filed 2024-03-12 | $39.16M 10-K · filed 2024-03-12 | $39.16M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $9.27M 10-Q · filed 2023-11-08 | $17.76M derived: sum of 2 quarters · filed 2023-11-08 | $28.29M 10-Q · filed 2023-11-08 | $37.21M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $8.49M 10-Q · filed 2023-08-09 | $19.01M 10-Q · filed 2023-08-09 | $27.94M derived: sum of 3 quarters · filed 2023-08-09 | $37.13M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $10.52M 10-Q · filed 2023-05-10 | $19.45M derived: sum of 2 quarters · filed 2023-05-10 | $28.65M derived: sum of 3 quarters · filed 2023-05-10 | $34.97M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $8.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $18.12M derived: sum of 2 quarters · filed 2023-03-15 | $24.45M derived: sum of 3 quarters · filed 2023-03-15 | $30.25M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $9.20M 10-Q · filed 2022-11-09 | $15.52M derived: sum of 2 quarters · filed 2022-11-09 | $21.32M 10-Q · filed 2022-11-09 | $28.93M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $6.32M 10-Q · filed 2022-08-10 | $12.13M 10-Q · filed 2022-08-10 | $19.73M derived: sum of 3 quarters · filed 2022-08-10 | $25.76M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $5.80M 10-Q · filed 2022-05-09 | $13.41M derived: sum of 2 quarters · filed 2022-05-09 | $19.44M derived: sum of 3 quarters · filed 2022-05-09 | $24.12M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $13.63M derived: sum of 2 quarters · filed 2022-03-22 | $18.32M derived: sum of 3 quarters · filed 2022-03-22 | $23.40M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $6.03M 10-Q · filed 2021-11-10 | $10.71M derived: sum of 2 quarters · filed 2021-11-10 | $15.79M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $4.68M 10-Q · filed 2021-09-13 | $9.77M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $19.12M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |